To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, Department of Health and Human Services, Food and Drug Administration, for fiscal year 2024.

Bill 118 hr 2295, also known as the "Limitation on Availability of Funds for FDA Act," aims to place restrictions on the amount of funds available for the Food and Drug Administration (FDA) within the Department of Health and Human Services for the fiscal year 2024. The bill seeks to limit the FDA's budget in order to ensure more efficient use of taxpayer dollars and to hold the agency accountable for its spending.

The bill does not specify the exact amount of the budget limitation, but rather sets a general restriction on the availability of funds for the FDA. This means that the agency will have to operate within a set budget cap, which could potentially impact its ability to carry out certain programs and initiatives.

Supporters of the bill argue that placing limitations on the FDA's budget will encourage the agency to prioritize its spending and focus on its core responsibilities. They believe that this will lead to greater efficiency and effectiveness in the FDA's operations. Opponents of the bill, however, are concerned that restricting the FDA's budget could hinder the agency's ability to protect public health and safety. They argue that the FDA plays a crucial role in regulating food and drug products, and that cutting its funding could have negative consequences for consumers. Overall, Bill 118 hr 2295 raises important questions about the balance between fiscal responsibility and the need for strong regulatory oversight. It will be important for lawmakers to carefully consider the potential impacts of limiting the FDA's budget before making a final decision on the bill.